Sutro Biopharma, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own0.10% Shs Outstand57.48M Perf Week-7.33%
Market Cap269.59M Forward P/E- EPS next Y-2.82 Insider Trans0.00% Shs Float54.06M Perf Month-19.46%
Income-122.70M PEG- EPS next Q-0.62 Inst Own91.30% Short Float / Ratio2.92% / 3.02 Perf Quarter-32.82%
Sales69.80M P/S3.86 EPS this Y-132.00% Inst Trans13.21% Short Interest1.58M Perf Half Y-13.25%
Book/sh4.39 P/B1.07 EPS next Y-17.00% ROA-34.30% Target Price22.12 Perf Year-44.26%
Cash/sh5.65 P/C0.83 EPS next 5Y- ROE-53.80% 52W Range3.33 - 9.16 Perf YTD-42.88%
Dividend- P/FCF- EPS past 5Y- ROI-35.50% 52W High-49.62% Beta0.93
Dividend %- Quick Ratio5.90 Sales past 5Y0.70% Gross Margin- 52W Low38.59% ATR0.33
Employees259 Current Ratio5.90 Sales Q/Q195.30% Oper. Margin- RSI (14)24.26 Volatility6.00% 6.09%
OptionableYes Debt/Eq0.08 EPS Q/Q44.40% Profit Margin- Rel Volume0.32 Prev Close4.70
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume523.84K Price4.61
Recom1.80 SMA20-12.70% SMA50-25.96% SMA200-26.46% Volume139,519 Change-1.81%
Mar-21-23Downgrade Wells Fargo Overweight → Equal Weight $15 → $8
Aug-18-22Resumed Wells Fargo Overweight $15
Jun-18-21Initiated H.C. Wainwright Buy $35
Dec-03-20Initiated Stifel Buy $25
Sep-02-20Initiated Jefferies Buy $21
Jul-16-20Initiated Wells Fargo Overweight $18
Jan-13-20Initiated SunTrust Buy $18
Oct-07-19Initiated BTIG Research Buy $19
Jul-18-19Initiated Deutsche Bank Buy $22
Apr-29-19Initiated H.C. Wainwright Buy $18
Show Previous Ratings
Mar-17-23 04:01PM
Mar-05-23 09:17AM
Mar-01-23 08:00AM
Feb-28-23 08:00AM
Feb-17-23 04:01PM
06:31AM Loading…
Jan-27-23 06:31AM
Jan-10-23 09:06AM
Jan-09-23 04:05PM
Jan-06-23 01:48PM
Jan-04-23 08:00AM
Dec-21-22 08:00AM
Dec-20-22 04:05PM
Dec-17-22 07:42AM
Dec-10-22 10:30AM
Nov-23-22 07:00AM
07:07AM Loading…
Nov-20-22 07:07AM
Nov-11-22 09:55AM
Nov-08-22 05:45PM
Nov-03-22 09:00AM
Nov-02-22 10:00AM
Oct-24-22 07:00AM
Oct-21-22 09:55AM
Oct-05-22 09:55AM
Sep-26-22 09:39AM
Sep-19-22 11:58AM
Sep-01-22 07:00AM
Aug-29-22 09:55AM
04:01PM Loading…
Aug-19-22 04:01PM
Aug-11-22 09:55AM
Aug-08-22 06:05PM
Aug-03-22 07:00AM
Jul-28-22 08:07AM
Jul-26-22 04:01PM
Jul-12-22 07:00AM
Jun-29-22 11:51AM
Jun-28-22 12:25PM
Jun-27-22 07:31PM
Jun-03-22 04:01PM
Jun-02-22 07:00AM
May-14-22 08:02AM
May-09-22 05:45PM
May-05-22 05:35PM
Apr-29-22 05:00PM
Apr-19-22 09:30AM
Apr-08-22 01:00PM
Apr-05-22 07:00AM
Mar-30-22 04:05PM
Mar-21-22 01:39PM
Mar-03-22 07:00AM
Feb-28-22 04:35PM
Feb-18-22 11:21AM
Feb-17-22 02:38AM
Jan-07-22 08:48AM
Jan-06-22 04:34PM
Jan-05-22 04:30PM
Dec-27-21 07:00AM
Dec-17-21 01:38PM
Dec-13-21 07:00AM
Nov-22-21 07:00AM
Nov-17-21 07:00AM
Nov-10-21 08:55AM
Nov-02-21 07:00AM
Oct-28-21 03:05PM
Oct-19-21 11:19AM
Oct-13-21 03:07AM
Oct-12-21 07:00AM
Sep-30-21 09:18AM
Sep-29-21 10:26AM
Sep-17-21 05:00PM
Sep-16-21 07:00AM
Sep-01-21 07:00AM
Aug-19-21 09:35AM
Aug-18-21 07:37AM
Aug-11-21 08:12AM
Aug-09-21 08:35AM
Aug-05-21 10:50AM
Jul-29-21 03:05PM
Jul-13-21 11:11AM
Jun-21-21 04:42PM
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBINI EDWARD CCFO and SecretaryFeb 13Option Exercise5.8145,698265,41476,406Feb 14 05:12 PM
NEWELL WILLIAM JCEOJan 27Option Exercise0.0013,7500137,787Jan 31 05:31 PM
FITZPATRICK LINDA AChief People & Comm. OfficerJan 27Option Exercise0.008,250044,574Jan 31 05:29 PM
Hallam TrevorPres. Rsrch & Cf. Sctific OfcrJan 27Option Exercise0.005,250085,521Jan 31 05:27 PM
Vasquez NickiChief Port. Strat & Alnce OfcrJan 27Option Exercise0.002,500016,620Jan 31 05:24 PM
Shabbir AnikChief Technical Ops. OfficerJan 27Option Exercise0.004,500032,259Jan 31 05:21 PM
ALBINI EDWARD CCFO and SecretaryJan 27Option Exercise0.005,250032,848Jan 31 05:19 PM
Chung JaneChief Commercial OfficerAug 09Option Exercise0.0018,750021,250Aug 10 06:16 PM
Vasquez NickiChief Port. Strat & Alnce OfcrJul 12Option Exercise0.003,250015,243Jul 13 06:24 PM
Hallam TrevorPres. Rsrch & Cf. Sctific OfcrApr 14Option Exercise0.003,750081,567Apr 15 07:19 PM